BRUSSELS |
Mon Sep 2, 2013 12:00pm EDT
BRUSSELS (Reuters) – Belgian biotech group Thrombogenics said on Monday that its main drug Jetrea, which treats eye disease, was recommended for reimbursement by British healthcare cost watchdog NICE.
Jetrea, which treats…
British cost watchdog recommends Thrombogenics eye drug
No comments:
Post a Comment